NYSE:JNJ - Johnson & Johnson Stock Price, News, & Analysis

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Johnson & Johnson announced a quarterly dividend on Thursday, October 18th. Investors of record on Tuesday, November 27th will be paid a dividend of $0.90 per share on Tuesday, December 11th. This represents a $3.60 annualized dividend and a yield of 2.71%. The ex-dividend date is Monday, November 26th. View Johnson & Johnson's Dividend History.

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Tuesday, October, 16th. The company reported $2.05 EPS for the quarter, beating the Zacks' consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. Johnson & Johnson's revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm earned $1.90 earnings per share. View Johnson & Johnson's Earnings History.

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Johnson & Johnson.

Johnson & Johnson will be holding an earnings conference call on Tuesday, January 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Johnson & Johnson updated its FY18 earnings guidance on Monday, October, 29th. The company provided earnings per share (EPS) guidance of $8.13-8.18 for the period, compared to the Thomson Reuters consensus estimate of $8.16.

15 brokers have issued twelve-month target prices for Johnson & Johnson's stock. Their forecasts range from $110.00 to $160.00. On average, they anticipate Johnson & Johnson's stock price to reach $142.2727 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Johnson & Johnson.

Media stories about JNJ stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Johnson & Johnson earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN).

Johnson & Johnson's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.96%), Vanguard Group Inc (7.96%), Bank of New York Mellon Corp (1.26%), Massachusetts Financial Services Co. MA (1.11%), Morgan Stanley (0.85%) and Legal & General Group Plc (0.48%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

JNJ stock was sold by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Trust & Banking Corp, Fisher Asset Management LLC, American Century Companies Inc., Skandinaviska Enskilda Banken AB publ , Russell Investments Group Ltd., Massachusetts Financial Services Co. MA, Assenagon Asset Management S.A. and Janus Henderson Group PLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.

JNJ stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Morgan Stanley, Los Angeles Capital Management & Equity Research Inc., Mondrian Investment Partners LTD, Cornerstone Wealth Management LLC, Flossbach Von Storch AG and Bank of New York Mellon Corp. View Insider Buying and Selling for Johnson & Johnson.

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JNJ stock can currently be purchased for approximately $133.00.

Johnson & Johnson has a market capitalization of $356.83 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

The official website for Johnson & Johnson is http://www.jnj.com.

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.